Table 3. Dose reductions in patients with markers of poor prognosis.

Factor	nab-P + Gem				Gem
	n	nab-P DR, %	Gem DR, %		n	DR, %
Age
<65 years	246	40	45		225	32
≥65 years	175	42	50		177	33
Karnofsky performance status
90-100	246	42	50		248	36
70-80	174	40	43		153	28

DR, dose reduction; Gem, gemcitabine; nab-P, nab-paclitaxel.